Age-associated CVDs impose a great burden on current health systems. Despite the fact that current strong evidence supports the links among aging, telomere attrition, and CVDs, there is no clear direction for the development of telomere therapeutics against CVDs.
Traditional risk factors for cardiovascular diseases (CVD), such as smoking, diabetes mellitus, dyslipidemia, hypertension, obesity, and shift work, have been associated with short LTL (8) . In the prospective
WOSCOPS (West of Scotland Primary Prevention
Study) trial, subjects in the lowest tertile of LTL had a 44% increased risk of 5-year major cardiovascular events compared with subjects in the highest tertile of LTL (9) . Another meta-analysis study with 43,725 participants and 8,400 patients revealed that short LTL had a pooled relative risk for coronary heart disease of 1.54 (95% confidence interval: 1.30 to 1.83).
In addition, short LTL was associated with coronary artery disease risk independent of traditional vascular risk factors. The association of short LTL with cerebrovascular disease is less significant than that with coronary artery disease (10) . Short LTL also affects the prognosis of coronary artery disease. In a prospective WHI (Women's Health Initiative) study with 1,525 post-menopausal women, shorter LTL was associated with higher risks of mortality (11) . Further analysis showed that patients with myocardial infarction had shorter LTL, which was equivalent to that observed in individuals without myocardial infarction but who were 8 to 12 years older in biological age (12) . Shorter LTL was also associated with increased proinflammatory activity in high-risk unstable plaque on virtual histology intravascular ultrasound (13) and delayed re-endothelialization after drug-eluting stent implantation (14) in acute coronary syndrome. When patients developed chronic heart failure, they were also observed to have shorter LTL (15) . Moreover, short LTL was also associated with congestive heart failure severity and clinical outcomes (16) .
Despite the fact that current robust epidemiological and animal study evidence supports the telomere attrition links between age and CVDs, there is no clear route that leads to the development of telomere therapeutics against CVDs in the future due to the following limitations. First, in adult somatic cells, manipulation of the telomere system bears an oncogenic risk (17, 18) . Thus, therapeutic techniques based on the overexpression of telomerase and other telomere-related signals should be applied after considering cell-type and tissue interactions. Second, there is still no clear mechanistic insight into the link between telomere and/or telomerase and atherosclerosis development (19) . Third, the telomere system is complex and regulated by various feedback mechanisms, including circadian rhythm oscillations (20) , and a direct interruption of 1 target in the telomere pathway can lead to various side effects.
TELOMERES AND TELOMERASE
Because DNA polymerase is unable to replicate the 3 0 ends of chromosomes fully, the so-called "endreplication problem," telomeres shorten during each cell replicated cycle (21) . When telomeres reach a critically short length, genomic instability activates the DNA repair system and induces replicative arrest, senescence, and cell death (22) .
In primary human cells, each time a cell divides, 50 to 100 bases are lost from the telomeres on each chromosome. This loss is much larger than the estimation from end-replication mechanisms, indicating that there are other contributing factors for telomere attrition in human cells (23) . Oxidative stress and tissue inflammation have been observed to accelerate telomere shortening and reduced replicative lifespans (24) . Telomere shortening is considered a biological molecular clock and is the underlying mechanism proposed to explain the limited lifespan of cells in culture, known as the Hayflick limit (25) . During the progressive accumulation of senescent cells in aging,
there is a marked increase in the secretion of proinflammatory cytokines, adhesion molecules, growth factors, and proteases from senescent cells (26, 27) . This inflammatory signaling initiates a vicious cycle that enhances telomere dysfunction, triggers replicative senescence, and promotes aging and development of age-associated diseases (28) .
Telomerase is a crucial component in telomere maintenance and regulation. It consists of an RNA Yeh et al.
Telomeres as Therapeutic Targets proof-of-concept experimental data in mice, the development of safe strategies for transient and controllable telomerase activation in humans can be a subject of future studies.
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PHARMACEUTICAL INTERVENTIONS FOR TELOMERES AND TELOMERASE ACTIVITY
Because of the pertinence of telomerase in antiaging gene therapy in mice models, several studies The human telomerase complex consists of human telomerase reverse transcriptase (TERT), telomerase RNA component (TERC), dyskerin, and ribonucleoproteins (GAR1, NHP2, and NOP10). The telomerase complex protects chromosome ends by lengthening telomeres in DNA strands.
TERT is responsible for catalyzing the addition of DNA nucleotides to the ends of telomeres. TERC serves as an RNA template for telomere replications by TERT. Shelterin complex protects telomeres and regulates telomerase activity. Shelterin has 6 subunits, including telomere repeat binding factor 1 (TRF1), telomere repeat binding factor 2 (TRF2), repressor/activator protein 1 (RAP1), protection of telomere 1 (POT1), TRF1-and TRF2-interacting nuclear protein 2 (TIN2), and ACD shelterin complex subunit and telomerase recruitment factor (TPP1).
Without telomerase, telomeres lose approximately 120 bp of DNA in human cells. Shortened and dysfunctional telomeric ends will result in genomic instability, tumorigenesis, and cardiovascular aging.
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INFLAMMATION, ATHEROSCLEROSIS, AND CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL
Atherosclerosis is the dominant pathology of CVD, including myocardial infarction, heart failure, stroke, and peripheral artery diseases (68) . The prevalence of these diseases progressively increases with age. In addition, the risk factors of atherosclerotic diseases, such as aging, smoking, obesity, sedentary lifestyle, and unhealthy diet, have been reported to be associated with telomere shortening based on observational epidemiological studies (69) . As observed in 1 of these studies, each kilobase pair shortening of telomeres in peripheral blood cells was estimated to result in 2.8- 
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Telomeres as Therapeutic Targets these effects were only specific to cardiomyocytes, regardless of the age of the patients (74 Telomerase is active in the human coronary artery 
AGING CARDIOVASCULAR PATIENTS AND TELOMERE THERPAY
According to World Health Organization data, by 2020, all countries across the world will face significant challenges to their health and social systems due to the aging demographic shift (109) . The number of people aged 60 years and older will outnumber children younger than 5 years. The pace of the aging population will be faster in future decades. There are 3 significant differences in telomere therapy between the young and older adult population. First, in older adult individuals, the evidence supporting the telomere length and remaining lifespan is controversial (110) . The contradictory results of these studies suggest that in septuagenarians and octogenarians, the role of telomere in survival becomes less important (111) . A recent study indicated that healthy lifestyle habits such as not smoking and not being obese at the age of 71 were the most significant associated factors with survival at the age of 85 years or older in men (112) . The efficacy of manipulation of the telomere system with younger subjects versus older subjects will need exploratory studies in the future. Second, the goals of telomere cardiovascular therapy in young subjects and older adults subjects are different. In young subjects, the goal of telomere therapy is to prevent cardiovascular senescence and diseases, whereas in older adult subjects, the goal of telomere therapy is to restoration of cardiovascular functions.
Third, the prevention of CHIP and atherosclerosis with telomere targets in young subjects requires long- 
